Effects of the Angiotensin Converting Enzyme Inhibitor Captopril on Experimental Autoimmune Encephalomyelitis

References

• Ehlers M., Riordan J. F. Angiotensin-converting enzyme: new concepts regarding its biological role. Biochemistry 1989; 28: 5311–5317
   PubMed Web of Science ®Google Scholar
• Hooper N. Angiotensin converting enzyme: implications from molecular biology for its physiological functions. Int. J. Biochem. 1991; 23: 641–647
   PubMedGoogle Scholar
• Brownlees J., Williams C. H. Peptidases, peptides and the mammalian blood-brain barrier. J. Neurochem. 1993; 60: 793–803
   PubMed Web of Science ®Google Scholar
• Lieberman J. Elevation of angiotensin-converting-enzyme (ACE) level in sarcoidosis. Am. J. Med. 1975; 59: 365–372
   PubMed Web of Science ®Google Scholar
• Goto M., Fujisawa M., Yamada A., Okabe T., Takaku F., Sasano M., Nishioka K. Spontaneous release of angiotensin converting enzyme and interleukin 1β from peripheral blood monocytes from patients with rheumatoid arthritis under a serum free condition. Ann. Rheum. Dis. 1989; 49: 172–176
   Web of Science ®Google Scholar
• Goto M., Sasano M., Fuzisawa M., Okabe T., Nishizawa K. Constitutive production of angiotensin converting enzyme from rheumatoid nodule cells under serum free conditions. Ann. Rheum. Dis. 1992; 51: 741–742
   PubMed Web of Science ®Google Scholar
• Veale D., Yanni G., Bresnihan B., Fitz Gerald. O. Production of angiotensin converting enzyme by rheumatoid synovial membrane. Ann. Rheum. Dis. 1992; 51: 476–480
   PubMed Web of Science ®Google Scholar
• Weinstock J. V., Blum A. M. Isolated liver granulomas of murine Schistosoma mansoni contain components of the angiotensin system. J. Immunol. 1983; 131: 2529–2532
   PubMed Web of Science ®Google Scholar
• Weinstock J. V., Blum A. M., Kassab J. T. Angiotensin II is chemotactic for a T-cell subset which can express migration inhibition factor activity in murine schistosomiasis mansoni. Cell. Immunol. 1987; 107: 180–187
   PubMed Web of Science ®Google Scholar
• Weinstock J. V., Ehrinpreis M. N., Boros D. L., Gee J. B. Effect of SQ 14225, an inhibitor of angiotensin-I converting enzyme, on the granulomatous response to Schistosoma mansoni eggs in mice. J. Clin. Invest. 1981; 67: 931–936
   PubMed Web of Science ®Google Scholar
• Lieberman J., Sastre A. Serum angiotensin-converting enzyme: elevations in diabetes mellitus. Ann. Int. Med. 1980; 93: 825–826
   PubMed Web of Science ®Google Scholar
• Lieberman J., Rea T. Serum angiotensin converting enzyme in leprosy and coccidioidomycosis. Ann. Int. Med. 1977; 87: 422–425
   Web of Science ®Google Scholar
• Schweisfurth H., Wernze H. Changes in angiotensin converting enzyme in patients with viral hepatitis and liver cirrhosis. Acta Hepato-Gastroenterol. 1979; 26: 207–210
   PubMedGoogle Scholar
• Schweisfurth H., Schi S., öberg-Schiegnitz Kuhn W., Parusel B. Angiotensin I converting enzyme in the cerebrospinal fluid of patients with neurological diseases. Klin. Wochenschrift. 1987; 65: 955–958
   PubMedGoogle Scholar
• Cohen J., Constantinescu C., Grossman R., Goodman D. Serum angiotensin-conevrting enzyme in multiple sclerosis. Neurology 1994; 44: A211
   Google Scholar
• Foris G., Dezsö B., Medgyesi G. A., Füst G. Effect of angiotensin II on macrophage functions. Immunology 1983; 48: 529–535
   PubMed Web of Science ®Google Scholar
• Eisenlohr L. C., Bacik I., Bennink J. R., Bernstein K., Yewdell J. W. Expression of a membrane protease enhances presentation of endogenous antigens to MHC cals I-restricted T lymphocytes. Cell 1992; 71: 963–972
   PubMed Web of Science ®Google Scholar
• Kozlowski S., Corr M., Takeshita T., Boyd L. F., Pendleton C. D., Germain R. N., Berzofsky J. A., Margulies D. H. Serum angiotensin-1 converting enzyme activity processes a human immunodeficiency virus 1 gp160 peptide for presentation by major histocompatibilty complex class I molecules. J. Exp. Med. 1992; 175: 1417–1422
   PubMed Web of Science ®Google Scholar
• Kozlowski S., Corr M., Shirai M., Boyd L. F., Pendleton C. D., Berzofsky J. A., Margulies D. H. Multiple pathways are involved in the extracellular processing of MHC class I-restricted peptides. J. Immunol. 1993; 151: 4033–4044
   PubMed Web of Science ®Google Scholar
• Neefjes J. J., Momburg F. Cell biology of antigen presentation. Curr. Opin. Immunol. 1993; 5: 27–34
   PubMed Web of Science ®Google Scholar
• Johnsen S. A., Aurell M. Immunosuppressive action of captopril blocked by prostaglandin synthetase inhibitor. Lancet 1981; i: 1005
   Google Scholar
• Delfraissy J.-F., Galanaud P., Balavoine J.-F., Wallon C., Dormont J. Captopril and immune regulation. Kidney Int. 1984; 25: 959–929
   Web of Science ®Google Scholar
• Deepe G. S., Taylor C. L., Srivastava L., Bullock W. E. Impairment of granulomatous inflammatory response to Histoplasma capsulatum by inhibitors of angiotensin-converting enzyme. Infect. Immun. 1985; 48: 395–401
   PubMed Web of Science ®Google Scholar
• Herlitz H., Tarkowski A., Svalander C., Volkmann R., Westberg G. Beneficial effect of Captopril on systemic lupus erythematosus-like disease in MRL Ipr/Ipr mice. Int. Arch. Allergy Appl. Immunol. 1988; 85: 272–277
   PubMedGoogle Scholar
• Tarkowski A., Carlsten H., Herlitz H., Westberg G. Differential effects of captopril and enalapril, two angiotensin converting enzyme inhibitors, on immune reactivity in experimental lupus disease. Agents Actions 1990; 31: 96–101
   PubMedGoogle Scholar
• Jaffe I. Angiotensin converting enzyme inhibitors in rheumatoid arthritis. Arthritis Rheum. 1984; 27: 840
   PubMedGoogle Scholar
• Martin M. F. R., McKenna F., Bird H. A., Surrall K. E., Wright V. Captopril: a new treatment for rheumatoid arthritis?. Lancet 1984; ii: 1325–1327
   Google Scholar
• Hafler D. A., Weiner H. L. MS: a CNS and systemic autoimmune disease. Immunol. Today 1989; 10: 104–107
   PubMedGoogle Scholar
• Hallpike J. F., Adams C. W. M., Tourtellote W. W. “Multiple Sclerosis-Pathology, Diagnosis and Management.”. Chapman and Hall, London 1983
   Google Scholar
• Zamvil S. S., Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 1990; 8: 579–621
   PubMed Web of Science ®Google Scholar
• Matthews W. B., Compston A., Allen I. V., Martyn C. N. “McAlpine's Multiple Sclerosis.”. Churchill Livingstone, Edinburgh 1991
   Google Scholar
• Traugot U., Raine C. S. Muliple sclerosis. Evidence for antigen presentation in situ by endothelial cells and astrocytes. J. Neurol. Sci. 1985; 69: 365–370
   PubMed Web of Science ®Google Scholar
• Deibler G. E., Martenson R. E., Kies M. W. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep. Biochem. 1972; 2: 139–165
   PubMed Web of Science ®Google Scholar
• Shasha S. M., Nusam D., Labin L., Kristal B., Steinberger O., Barzilai M., Makov E., Shkolnik T. Effect of converting enzyme inhibitor captopril on T cell function in essential hypertension. Nephron. 1991; 59: 586–590
   PubMed Web of Science ®Google Scholar
• Kunkel S., Chensue S., SH P. Prostaglandins as endogenous mediators of interleukin 1 production. Journal of Immunology 1986; 136: 186–192
   PubMed Web of Science ®Google Scholar
• Renz J.-H., Gong H., Schmidt A., Nain M., Gemsa D. Release of tumor necrosis factor-α from macrophages. J. Immunol. 1988; 141: 2388
   PubMed Web of Science ®Google Scholar
• Endres S., Fülle H.-J., Sinha B., Stall D., Dinarello C. A., Gerzer R., Weber P. C. Cyclic nucleotides differentailly regulate the synthesis of tumor necrosis factor-a and interleukin-1β by human mononuclear cells. Immunology 1991; 72: 56
   PubMed Web of Science ®Google Scholar
• Ruddle N. Tumor necrosis factor (TNFα) and lymphotoxin (TNFβ). Curr. Opin. Immunol. 1992; 4: 327–332
   PubMed Web of Science ®Google Scholar
• Sharief M., Thompson E. In vivo realtionship of tumor necrosis factor-alpha to blodd-brain barrier damage in patients with acute multiple sclerosis. J. Neuroimmunol. 1992; 38: 27–33
   PubMed Web of Science ®Google Scholar
• Selmaj J., Raine C., Cross A. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol. 1991; 30: 694–700
   PubMed Web of Science ®Google Scholar
• Nataf S., Louboutin J. P., Chabannes D., Feve J. R., Muller J. Y. Pentoxifylline inhibits experimental allergic encephalomyelitis. Acta Neurol. Scand. 1993; 88: 97–99
   PubMed Web of Science ®Google Scholar
• Rott O., Cash E., Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1-but not type 2-associated lymphokine production, prevents induction of experiemntal autoimmune encepahlomyelitis in Lewis rats. Eur. J. Immunol. 1993; 23: 1745–1751
   PubMed Web of Science ®Google Scholar
• Pi X., Chen X. Captopril and ramiprilat protect against free radical injury in isolated working rat hearts. J. Molec. Cell. Cardiol. 1989; 21: 1261–1271
   PubMed Web of Science ®Google Scholar
• Jay D., Cuéllar A., Zamorano R., Muñoz E., Gleason R. Captopril does not scavenge superoxide: captopril prevents O2− production by chelating copper. Arch. Biochem. Biophys. 1991; 290: 463–467
   PubMed Web of Science ®Google Scholar
• Gillis C. N., Chen X., Merker M. M. Lisinopril and ramiprilat protection of the vascular endothelium against free radical-induced functional injury. J. Pharmacol. Exp. Therap. 1992; 262: 212–216
   PubMed Web of Science ®Google Scholar
• Rabkin S. W. Cilazapril and captopril accelerate recovery from hypoxia in myocardial cell aggregates in culture. J. Cardiovasc. Pharmacol. 1992; 19: 394–401
   PubMed Web of Science ®Google Scholar
• Langemann H., Kabiersch A., Newcombe J. Measurement of low-molecular weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. Eur. Neurol. 1992; 32: 248–252
   PubMed Web of Science ®Google Scholar
• Powell T., Sussman J. G., Davies-Jones G. A. B. MR imaging in acute multiple sclerosis: ringlike appearance in plaques suggesting the presence of paramagnetic free radicals. AJNR 1992; 13: 1544–1546
   PubMed Web of Science ®Google Scholar
• Toshniwal P. K., Zarling E. J. Evidence for increased lipid peroxidation in multiple sclerosis. Neurochem. Res. 1992; 17: 205–207
   PubMed Web of Science ®Google Scholar
• Banks W. A, Kastin A. J. Interactions between the blood-brain barrier and endogenous peptides-emerging clinical implications. Am. J. Med. Sci. 1988; 295: 459–465
   PubMed Web of Science ®Google Scholar
• Segal M. B., Zlokovic B. V. “The Blood-Brain Barrier, Amino Acids and Peptides.”. Kluwer, Dordrecht 1990
   Google Scholar
• Sorbi D., Fadly M., Hicks R., Alexander S., Arbeit L. Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. Kindey Int. 1993; 44: 1266–1272
   PubMed Web of Science ®Google Scholar
• Rosenberg G. A., Kornfeld M., Estrada E., Kelley R. O.L., Liotta A. W. G. Stetler-Stevenson. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res. 1992; 576: 203–207
   PubMed Web of Science ®Google Scholar
• Smith M. E. Proteolytic enzymes in demyelination. Neurochem. Clin. Neurol. 1980; 1: 1–10
   Google Scholar
• Bird H. A., LeGallez P., Dixon J. S., Catalano M. A., Traficante A., Liauw L., Sussman H., Rotman H., Wright V. A clinical and bichemical assessment of a nonthiol ACE inhibitor (Pentopril; CGS-13945) in active rheumatoid arthritis. J. Rheumatol. 1990; 17: 603–608
   PubMed Web of Science ®Google Scholar
• Brosnan C., Goldmuntz E., Cammer W., Factor S., Bloom B., Norton W. Prazosin, an α1-adrenergic receptor antagonist, suppresses experimental autoimmune encephalomyelitis in the Lewis rat. Proc. Natl. Acad. Sci. USA 1985; 82: 5915–5919
   PubMed Web of Science ®Google Scholar
• Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. JACC 1983; 2: 755–763
   Google Scholar
• Lewis E., Hunsicker L., Bain R., Rhode R. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. New Engl. J. Med. 1993; 329: 1456–1462
   PubMed Web of Science ®Google Scholar
• Testa M., Anderson R., Nackley J., Hollenberg N. Quality of Life Hypertension Study Group. Quality of life and antihypertensive therapy in men-a comparison of captopril and enalapril. New Engl. J. Med. 1993; 328: 907–913
   PubMed Web of Science ®Google Scholar
• Hafler D., Fox D., Manning M., Schlossman S., Reinherz E., Weiner H. In vivo activated T lymphocytes in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. New Engl J. Med. 1985; 213: 1405–1411
   Google Scholar